RVNC - Revance Therapeutics GAAP EPS of -$1.63 misses by $0.69 revenue of $56.8M misses by $1.94M
2023-11-08 16:23:27 ET
- Revance Therapeutics press release ( NASDAQ: RVNC ): Q3 GAAP EPS of -$1.63 misses by $0.69 .
- Revenue of $56.8M (+95.9% Y/Y) misses by $1.94M .
- Expects its 2023 GAAP operating expenses to be $545 million to $585 million.
- Cash, cash equivalents and short-term investments as of September 30, 2023 were $300.2 million.
- With current cash, cash equivalents, short-term investments and anticipated revenues and expenditures, management projects that the company will be funded to cash flow break-even and expects to reach positive Adjusted EBITDA in 2025.
For further details see:
Revance Therapeutics GAAP EPS of -$1.63 misses by $0.69, revenue of $56.8M misses by $1.94M